Abstract
A series of mono-morpholino 1,3,5-triazine derivatives (8a-8q) bearing a 3-oxa-8-azabicyclo[3.2.1]octane were prepared and evaluated for PI3-kinase/mTOR activity. Replacement of one of the bis-morpholines in lead compound 1 (PKI-587) with 3-oxa-8-azabicyclo[3.2.1]octane and reduction of the molecular weight yielded 8m (PKI-179), an orally efficacious dual PI3-kinase/mTOR inhibitor. The in vitro activity, in vivo efficacy, and PK properties of 8m are discussed.
Copyright © 2010. Published by Elsevier Ltd.
MeSH terms
-
Administration, Oral
-
Animals
-
Cell Line, Tumor
-
Humans
-
Mice
-
Mice, Nude
-
Morpholines / chemical synthesis
-
Morpholines / chemistry*
-
Morpholines / pharmacokinetics
-
Phosphatidylinositol 3-Kinase / metabolism
-
Phosphoinositide-3 Kinase Inhibitors*
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry*
-
Protein Kinase Inhibitors / pharmacokinetics
-
Structure-Activity Relationship
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
-
TOR Serine-Threonine Kinases / metabolism
-
Triazines / chemical synthesis
-
Triazines / chemistry*
-
Triazines / pharmacokinetics
-
Tropanes / chemistry
-
Urea / analogs & derivatives*
-
Urea / chemical synthesis
-
Urea / chemistry
-
Urea / pharmacokinetics
-
Xenograft Model Antitumor Assays
Substances
-
Morpholines
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors
-
Triazines
-
Tropanes
-
Urea
-
1-(4-(4-(3-oxa-8-azabicyclo(3.2.1)octan-8-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea
-
Phosphatidylinositol 3-Kinase
-
TOR Serine-Threonine Kinases